drugset / Trial / NCT00081458

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458

Phase 3 Completed 84 enrolled Shire
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

Timeline

Start
2004-05-25
Primary completion
2007-07-06
Completion
2007-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Teduglutide Peptide 0.05 mg/kg Subcutaneous
Subject Teduglutide Peptide 0.1 mg/kg Subcutaneous

Indications